GlassScriptPhysician profile
Steven M Troy
NPI 1720125586
$1,309.22
in general payments reported to CMS, 2019-2025
25 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $200 · 2021: $68.79 · 2023: $112 · 2024: $193 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.10 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.52 | 2019-2024 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $108.77 | 2019-2025 | Veozah |
| Sage Therapeutics, LLC | $102.37 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $92.88 | 2019-2020 | |
| Therapeuticsmd, INC. | $80.73 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $60.83 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $53.89 | 2023-2025 | Strensiq |
| Lupin INC. | $52.48 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $52.28 | 2023-2025 | Myfembree |
| Dysis Medical, INC. | $50.56 | 2019 | |
| Aspira Women'S Health INC | $49.11 | 2025 | Ova1 |
| Allergan, INC. | $48.98 | 2019 | |
| Covidien LP | $44.04 | 2019 | |
| Coopersurgical, INC. | $40.03 | 2024 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $36.65 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.93 | 2019 | |
| Amgen INC. | $21.41 | 2025 | |
| Pfizer INC. | $20.29 | 2025 | |
| Duchesnay USA Incorporated | $18.27 | 2020 | |
| Shield Therapeutics INC | $14.59 | 2025 | |
| Evofem Biosciences, INC. | $14.52 | 2024 | |
| Avion Pharmaceuticals | $14.48 | 2020 | |
| Almatica Pharma LLC | $14.01 | 2025 | Teriparatide |
| Hologic Sales and Service, LLC | $11.44 | 2021 | |
| Exeltis, USA INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Troy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.